Pharsight

Drugs that contain Olutasidenib

1. Rezlidhia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9834539 RIGEL PHARMS INC Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Sep, 2035

(11 years from now)

US10532047 RIGEL PHARMS INC Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
May, 2039

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11498913 RIGEL PHARMS INC Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Sep, 2035

(11 years from now)

US10414752 RIGEL PHARMS INC Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Sep, 2035

(11 years from now)

US10550098 RIGEL PHARMS INC Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Sep, 2035

(11 years from now)

US11497743 RIGEL PHARMS INC Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation
May, 2039

(14 years from now)

US10959994 RIGEL PHARMS INC Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
May, 2039

(14 years from now)

US11376246 RIGEL PHARMS INC Inhibiting mutant IDH-1
May, 2039

(14 years from now)

US11013734 RIGEL PHARMS INC Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
May, 2039

(14 years from now)

US11013733 RIGEL PHARMS INC Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
May, 2039

(14 years from now)

US11738018 RIGEL PHARMS INC Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
Jul, 2039

(15 years from now)

US11723905 RIGEL PHARMS INC Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
Nov, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 01, 2027
Orphan Drug Exclusivity(ODE-413) Dec 01, 2029

NCE-1 date: 01 December, 2026

Market Authorisation Date: 01 December, 2022

Treatment: A method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehydrogenase-1 (idh1) mutation; A method of treating a cancer characterized by an idh1 mutation where the cancer is ac...

Dosage: CAPSULE;ORAL

More Information on Dosage

REZLIDHIA family patents

Family Patents